Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,035 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma.
Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G, Smith GM, Parker A, Schey S, Chopra R, Hatton C, Tighe J, Hunter A, Peggs K, Linch D, Goldstone A, Mackinnon S. Morris E, et al. Among authors: cook g. Blood. 2004 Dec 15;104(13):3865-71. doi: 10.1182/blood-2004-03-1105. Epub 2004 Aug 10. Blood. 2004. PMID: 15304395 Free article.
Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study.
Delgado J, Thomson K, Russell N, Ewing J, Stewart W, Cook G, Devereux S, Lovell R, Chopra R, Marks DI, Mackinnon S, Milligan DW; British Society of Blood and Marrow Transplantation. Delgado J, et al. Among authors: cook g. Blood. 2006 Feb 15;107(4):1724-30. doi: 10.1182/blood-2005-08-3372. Epub 2005 Oct 20. Blood. 2006. PMID: 16239425 Free article. Clinical Trial.
Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia.
Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G, Marsh J, Milligan D, Goldstone A, Hunter A, Khwaja A, Chopra R, Littlewood T, Peniket A, Parker A, Jackson G, Hale G, Cook M, Russell N, Mackinnon S. Tauro S, et al. Among authors: cook m, cook g. J Clin Oncol. 2005 Dec 20;23(36):9387-93. doi: 10.1200/JCO.2005.02.0057. Epub 2005 Nov 28. J Clin Oncol. 2005. PMID: 16314618 Clinical Trial.
The outcome of sibling and unrelated donor allogeneic stem cell transplantation in adult patients with acute myeloid leukemia in first remission who were initially refractory to first induction chemotherapy.
Cook G, Clark RE, Crawley C, Mackinnon S, Russell N, Thomson K, Pearce RM, Towlson K, Marks DI. Cook G, et al. Biol Blood Marrow Transplant. 2006 Mar;12(3):293-300. doi: 10.1016/j.bbmt.2005.10.019. Biol Blood Marrow Transplant. 2006. PMID: 16503498 Free article.
Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission.
Patel B, Kirkland KE, Szydlo R, Pearce RM, Clark RE, Craddock C, Liakopoulou E, Fielding AK, Mackinnon S, Olavarria E, Potter MN, Russell NH, Shaw BE, Cook G, Goldstone AH, Marks DI. Patel B, et al. Among authors: cook g. Haematologica. 2009 Oct;94(10):1399-406. doi: 10.3324/haematol.2009.008649. Epub 2009 Jul 31. Haematologica. 2009. PMID: 19648167 Free PMC article.
Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia.
Craddock C, Nagra S, Peniket A, Brookes C, Buckley L, Nikolousis E, Duncan N, Tauro S, Yin J, Liakopoulou E, Kottaridis P, Snowden J, Milligan D, Cook G, Tholouli E, Littlewood T, Peggs K, Vyas P, Clark F, Cook M, Mackinnon S, Russell N. Craddock C, et al. Among authors: cook m, cook g. Haematologica. 2010 Jun;95(6):989-95. doi: 10.3324/haematol.2009.013920. Epub 2009 Nov 30. Haematologica. 2010. PMID: 19951968 Free PMC article.
T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma.
Thomson KJ, Morris EC, Milligan D, Parker AN, Hunter AE, Cook G, Bloor AJ, Clark F, Kazmi M, Linch DC, Chakraverty R, Peggs KS, Mackinnon S. Thomson KJ, et al. Among authors: cook g. J Clin Oncol. 2010 Aug 10;28(23):3695-700. doi: 10.1200/JCO.2009.26.9100. Epub 2010 Jul 6. J Clin Oncol. 2010. PMID: 20606089 Clinical Trial.
2,035 results